Prostate mapping involves using two advanced prostate biopsy technologies in a single procedure. On the one hand, the MRI-US fusion biopsy and on the other hand, micro-ultrasound-guided biopsy ExactVu, a symbiosis that gives the specialist greater precision in the diagnosis of prostate cancer.
The 3 Tesla Multiparametric Magnetic Resonance Imaging locates areas of suspicion of prostate cancer The BIOPSEE MRI-ultrasound fusion system merges MRI images with ultrasound images obtained in the operating room, allowing the biopsy to be precisely targeted to the areas of the prostate of interest. This ensures that the biopsy is taken precisely from the suspicious areas visualized on the MRI. The biopsy is performed on an outpatient basis through the perineal skin, not through the rectum.
Unfortunately, prostate MRI does not detect all prostate tumors, only about 80%. The use of the ExactVu micro-ultrasound system, a high-resolution ultrasound 300 times greater than conventional ultrasound, allows visualization of tumors that MRI cannot detect. Combining these two technologies in the same procedure improves the identification of suspicious lesions and increases diagnostic accuracy, thus enabling the specialist to make the most appropriate treatment decision for the patient.
The effectiveness of this diagnostic technique has been proven by our team, which has achieved worldwide recognition by creating the “Madrid Protocol”This protocol is based on our unit's own experience and was published in the Journal of Urology, the scientific journal of the American Urological Association.
With the development of this protocol, our team has become the first in the world to analyze micro-ultrasound-guided biopsy (Micro-US) and mpMRI fusion biopsy in the same procedure. The research has evaluated the accuracy of these methods in detecting the prostate cancer and found that adding microultrasound to fusion biopsy increased the diagnosis of clinically significant tumors.
This study analyzed data from 194 patients who underwent the test between February 2018 and September 2019. The research, published in numerous scientific journals, concludes that this detection method is highly accurate. prostate cancer and the absence of infectious complications.
